|Over a week ago|
VBI Vaccines price target raised to $8 from $5 at Oppenheimer » 07:1406/2306/23/20
Oppenheimer analyst Leland Gershell raised the firm's price target on VBI Vaccines to $8 from $5 and keeps an Outperform rating on the shares. The analyst notes that new VBI-1901's maturing Phase 1/2a results in refractory glioblastoma, as presented at AACR, include improvement from Stable Disease to a confirmed durable Partial Response in one patient with this highly aggressive malignancy; and VBI's identification of a biomarker that may predict immunotherapeutic response. Gershell looks forward to an initial reveal with a more active adjuvant in Q4, and a GBM registration trial is slated to begin next year. The analyst has revised his financial model to better reflect his view of VBI's prospects as it advances this and other pipeline assets as well as SciB-Vac, any/all of which he believes could drive industry partnerships.
|Over a month ago|
Culper Research short VBI Vaccines, says shares 'worthless' » 09:2506/0206/02/20
In a recently published…
In a recently published report, Culper Research says it is short VBI Vaccines as it believes the company "is effectively an 'empty box' stock promotion and shares are worthless." "We believe the Company's claim to a revolutionary hepatitis B vaccine (Sci-B-Vac) has fallen flat on its face. VBI's Sci-B-Vac acquisition traces to a paltry $2 million transaction in 2012, orchestrated by long-time stock promoter Phillip Frost. Investors now cheer on prospects for US and European approvals, but the Company's feeble clinical data package and consequent inability to secure a 2-dose label renders the drug practically worthless, in our view.... In what we believe is most damning both to Sci-B-Vac's commercial prospects and to management's credibility, on March 23, 2020, the European Medicines Agency (EMA) revealed it had refused Sci-B-Vac's pediatric investigation plan (PIP), stating that Sci-B-Vac 'does not represent a significant therapeutic benefit over existing treatments.'... In what we believe is most damning both to Sci-B-Vac's commercial prospects and to management's credibility, on March 23, 2020, the European Medicines Agency (EMA) revealed it had refused Sci-B-Vac's pediatric investigation plan (PIP), stating that Sci-B-Vac "does not represent a significant therapeutic benefit over existing treatments'," the report reads. Reference Link
VBI Vaccines forms commercial advisory board » 08:0405/2805/28/20
VBI Vaccines announced…
VBI Vaccines announced the formation of a commercial advisory board consisting of experts in public health policy, epidemiology and vaccine development. The board will work closely with VBI's management team on pre-commercialization and commercialization activities and strategy for the company's pipeline programs. Members of the commercial advisory board are Damian Braga, a member of the company's board who will act as chairperson, Eddy Bresnitz, Michael Decker and John Grabenstein.
Big investment companies place cautious bets on COVID treatment race, WSJ says » 15:1005/1405/14/20
GILD, VBIV, VIR
As drug companies race to…
As drug companies race to discover treatments for the new coronavirus, big investment companies are placing cautious bets on likely winners, The Wall Street Journal's Gregory Zuckerman writes. Gilead (GILD) is up about 20% this year, thanks to remdesivir, but is among the stocks that has investors thinking twice, the author notes. Meanwhile, Robert Nelsen, who helps run venture-capital company Arch Venture Partners, which made early and successful bets on cancer immunotherapy, is backing VIR Biotechnology (VIR), which plans trials for its own monoclonal antibody therapy this summer, according to the report. Both Nelsen and Joseph Edelman, who runs Perceptive Advisors, also hold big chunks of ownership in VBI Vaccines (VBIV), an unproven biotech company claiming an experimental vaccine approach, Zuckerman adds.Reference Link
VBI Vaccines 45.455M share Spot Secondary priced at $1.10 » 09:1404/2204/22/20
Raymond James and…
Raymond James and Oppenheimer acted as joint book running managers for the offering.
Fly Intel: After-Hours Movers » 18:5804/2104/21/20
SNAP, USNA, CMG, TXN, NFLX, EXPE, GME, QTNT, IBKR, MANH, NAVI, VBIV
Check out this evening's…
VBI Vaccines announces common stock offering, no amount given » 16:0604/2104/21/20
VBI Vaccines announced…
VBI Vaccines announced that it has commenced an underwritten public offering of its common shares. VBI intends to use the net proceeds from the offering to support the regulatory filings, pre-commercialization, and launch planning activities for Sci-B-Vac in the United States, Europe, and Canada, for the continued advancement of its pipeline programs, including the development of VBI-1901, a cancer vaccine immunotherapeutic candidate for recurrent glioblastoma; VBI-2601, an immunotherapeutic candidate for chronic hepatitis B infection; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2901, a prophylactic pan-coronavirus vaccine candidate. The net proceeds will also be used for general corporate purposes, including working capital and capital expenditures. Raymond James and Oppenheimer are acting as joint book-running managers, and National Securities Corporation, a wholly-owned subsidiary of National Holdings, is acting as lead manager for the underwritten public offering.
|Over a quarter ago|
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital » 10:1803/3103/31/20
VBI Vaccines this morning…
VBI Vaccines this morning announced a collaboration with the National Research Council of Canada to develop a novel pan-coronavirus vaccine for protection against COVID-19, in addition to severe acute respiratory syndrome and Middle East respiratory syndrome, BMO Capital analyst Do Kim tells investors in a research note. With VBI's eVLP platform technology, the multivalent vaccine could express all three viral spike proteins, as well as target mutated coronavirus strains, contends the analyst. Kim expects a potential lead candidate in Q4 of this year, with the program as upside to estimates. The analyst keeps an Outperform rating on VBI Vaccines with a $5 price target. The stock in early trading is up 15% to $1.08.
VBI teams with National Research Council of Canada for COVID vaccine » 10:1303/3103/31/20
VBI Vaccines announced…
VBI Vaccines announced earlier today a collaboration with the National Research Council of Canada, Canada's largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The collaboration will combine VBI's viral vaccine expertise, eVLP technology platform, and coronavirus antigens with the NRC's COVID-19 antigens and assay development capabilities to identify the most immunogenic vaccine candidate for further development. Under the terms of the agreement, the NRC and VBI will collaborate to evaluate and select the optimal vaccine candidate. Following IND-enabling pre-clinical studies, VBI believes that clinical study materials could be available in Q4 2020. Said Francisco Diaz-Mitoma, VBI's Chief Medical Officer. "Coronaviruses are enveloped viruses by nature, which we believe makes them a prime target for VBI's flexible enveloped virus-like particle platform technology, ongoing development of which is led and conducted at our research facility in Ottawa, Canada. Based on past clinical experience with the eVLP platform, we expect that a multivalent eVLP vaccine candidate, co-expressing SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins on the same particle, will be possible to develop. Moreover, we believe the trivalent construct could allow for the production of broadly reactive antibodies, which offer potential for protection from mutated strains of COVID-19 that may emerge over time."
VBI Vaccines provides update on part A of VBI-1901 study » 08:1103/0303/03/20
VBI Vaccines provided an…
VBI Vaccines provided an update on Part A of the ongoing Phase 1/2a study of VBI-1901, the company's cancer vaccine immunotherapeutic candidate, for the treatment of patients with recurrent glioblastoma, or GBM. For patients who had an immunologic response to the vaccine, considered to be vaccine responders, the 12-month overall survival, or OS, rate was 83%, compared to 33% for vaccine non-responders. Similarly, among patients evaluable for response and survival in Part A, vaccine responders saw a 6.25-month improvement in median OS compared to vaccine non-responders. VBI-1901 continues to be safe and well-tolerated at all doses tested, with no safety signals observed. Expanded immunologic, tumor imaging, and clinical data from the Phase 2a part of the study are expected in Q2 and Q4. Additionally, efforts are underway to define biomarkers that may help identify patients more likely to respond to VBI-1901.